A novel human antitumor dimeric immuno RNase

Journal of Immunotherapy

Volumn 31, Issue 5, 2008, Pages 440-445

  Riccio, Gennaro ^a   Borriello, Marianna ^a   D'Alessio, Giuseppe ^a   De Lorenzo, Claudia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ErbB2; Human RNase; Immunotherapy; RNase inhibitor; ScFv

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN ERB HHP2 RNASE; RECOMBINANT PROTEIN; RIBONUCLEASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; DIMERIZATION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; PANCREAS; TUMOR CELL LINE;

CELL LINE, TUMOR; DIMERIZATION; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; NEOPLASMS; PANCREAS; RECEPTOR, ERBB-2; RIBONUCLEASES;

EID: 55249117282     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816bc769     Document Type: Article

References (18)

1. Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science. 1991;254:1173-1177. [PubMed: 1683495].
2. Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 1998;16:513-520. [PubMed: 9881483].
3. Weiner LM, O'Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recom-binant ricin. A immunoconjugate. Cancer Res. 1989;49:4062-4067. [PubMed: 2786751].
4. Schindler J, Sausville E, Messmann R, et al. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res. 2001;7:255-258. [PubMed: 11234876].
5. Rybak SM, Newton DL. Natural and engineered cytotoxic ribo-nucleases: therapeutic potential. Exp Cell Res. 1999;253:325-335. [PubMed: 10585255].
6. De Lorenzo C, Nigro A, Piccoli R, et al. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett. 2002;516:208-212. [PubMed: 11959134].
7. De Lorenzo C, Arciello A, Cozzolino R, et al. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res. 2004;64:4870-4874. [PubMed: 15256457].
8. De Lorenzo C, Di Malta C, Cali G, et al. Intracellular route and mechanism of action of Erb-hRNase, a human anti-ErbB2 anti-cancer immunoagent. FEBS Letters. 2007;581:296-300. [PubMed: 17208233].
9. D'Alessio G, Di Donato A, Mazzarella L, et al. Seminal ribonucleases: the importance of diversity. In: D'Alessio G, Riordan JF, eds. RNases: Structures and Function. New York: Academic Press; 1997:383-423.
10. Di Donato A, Cafaro V, D'Alessio G. Ribonuclease A can be transformed into a dimeric ribonuclease with antitumor activity. J Biol Chem. 1994;269:17394-17396. [PubMed: 8021240].
11. Piccoli R, Di Gaetano S, De Lorenzo C, et al. A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity towards malignant cells. Proc Natl Acad Sci USA. 1999;96:7768-7773. [PubMed: 10393896].
12. Di Gaetano S, D'Alessio G, Piccoli R. Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action. Biochem J. 2001;358:241-247. [PubMed: 11485573].
13. De Lorenzo C, Palmer DB, Piccoli R, et al. A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002;8: 1710-1719. [PubMed: 12060608].
14. Bartholeyns J, Wang D, Blackburn P, et al. Explanation of the observation of pancreatic ribonuclease activity at pH 4.5. Int J Pept Protein Res. 1977;10:172-175. [PubMed: 19366].
15. Naddeo M, Vitagliano L, Russo A, et al. Interactions of the cytotoxic RNase A dimers with the cytosolic ribonuclease inhibitor. FEBS Lett. 2005;579:2663-2668. [PubMed: 15862306].
16. Blank A, Sugiyama RH, Dekker CA. Activity staining of nucleolytic enzymes after sodium dodecyl-sulfate-polyacrylamide gel electrophoresis: use of aqueous isopropanol to remove detergent from gels. Anal Biochem. 1982;120:267-275. [PubMed: 6178316].
17. Deonarain MP, Epenetos AA. Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins. Br J Cancer. 1998;77:537-546. [PubMed: 9484808]
18. Deonarain MP, Epenetos AA. Targeting phosphodiesterases as a strategy for killing tumor cells. Cell Biophys. 1994;24-25:249-257. [PubMed: 7736530].